1. Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study
- Author
-
Laura A. Benjamin, Ross W. Paterson, Rachel Moll, Charis Pericleous, Rachel Brown, Puja R. Mehta, Dilan Athauda, Oliver J. Ziff, Judith Heaney, Anna M. Checkley, Catherine F. Houlihan, Michael Chou, Amanda J. Heslegrave, Arvind Chandratheva, Benedict D. Michael, Kaj Blennow, Vinojini Vivekanandam, Alexander Foulkes, Catherine J. Mummery, Michael P. Lunn, Stephen Keddie, Moira J. Spyer, Tom Mckinnon, Melanie Hart, Francesco Carletti, Hans Rolf Jäger, Hadi Manji, Michael S. Zandi, David J. Werring, Eleni Nastouli, Robert Simister, Tom Solomon, Henrik Zetterberg, Jonathan M. Schott, Hannah Cohen, and Maria Efthymiou
- Subjects
Medicine (General) ,R5-920 - Abstract
Background: A high prevalence of antiphospholipid antibodies has been reported in case series of patients with neurological manifestations and COVID-19; however, the pathogenicity of antiphospholipid antibodies in COVID-19 neurology remains unclear. Methods: This single-centre cross-sectional study included 106 adult patients: 30 hospitalised COVID-neurological cases, 47 non-neurological COVID-hospitalised controls, and 29 COVID-non-hospitalised controls, recruited between March and July 2020. We evaluated nine antiphospholipid antibodies: anticardiolipin antibodies [aCL] IgA, IgM, IgG; anti-beta-2 glycoprotein-1 [aβ2GPI] IgA, IgM, IgG; anti-phosphatidylserine/prothrombin [aPS/PT] IgM, IgG; and anti-domain I β2GPI (aD1β2GPI) IgG. Findings: There was a high prevalence of antiphospholipid antibodies in the COVID-neurological (73.3%) and non-neurological COVID-hospitalised controls (76.6%) in contrast to the COVID-non-hospitalised controls (48.2%). aPS/PT IgG titres were significantly higher in the COVID-neurological group compared to both control groups (p
- Published
- 2021
- Full Text
- View/download PDF